RxDoctor Payments Data

Bradley Keel, DO

Internal Medicine · Chattanooga, TNNPI 1003041641

Payments from drug & device makers

$4,052in general payments, 2019–2025

Across 197 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$542
  • Pfizer$531
  • Lilly USA, LLC$442
  • AbbVie$329
  • AstraZeneca$290
  • Amgen$207
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,052 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$52,434
Medicare patients
162
Services billed
1,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$54,117
EliquisApixaban42$44,596
TrulicityDulaglutide20$40,534
JardianceEmpagliflozin36$37,939
OzempicSemaglutide24$29,767
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$21,697
XareltoRivaroxaban19$21,260
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,910
Repatha SyringeEvolocumab14$8,387
Clorazepate Dipotassium13$2,880
ProgesteroneProgesterone, Micronized44$2,396
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$2,003
Duloxetine Hcl46$1,769
Levothyroxine Sodium152$1,475
Pantoprazole Sodium109$1,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$442$94,65170 claims
PfizerEliquis$531$44,59642 claims
Novo NordiskOzempic$542$29,76724 claims
AstraZenecaBreztri Aerosphere$290$21,69723 claims
Johnson & JohnsonXarelto$136$21,26019 claims
GSKTrelegy Ellipta$23$13,91016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →